Our Company
Eleanor N. Fish, CM, PhD, FAAS
Founder & President
Dr. Fish is a leading academic in immunology and women’s health, recognized internationally for her scientific and policy contributions. She is a Member of the Order of Canada and holds a Tier 1 Canada Research Chair in Women’s Health and Immunobiology. At the University of Toronto, she serves as Professor of Immunology and Pediatrics and Associate Chair for International Collaborations and Initiatives in Immunology. She is an Emerita Scientist at the Toronto General Hospital Research Institute, University Health Network, and a Fellow of the American Academy of Microbiology and the African Academy of Sciences. Dr. Fish has also served on the Expert Scientific Panel to the Chief Scientific Advisor and the Government of Canada COVID-19 Therapeutics Task Force.
- Your Title Goes Here 50%
MANAGEMENT
Ramtin Rahbar, PhD
Senior CMC Advisor
Dr. Rahbar is a distinguished senior executive in the field of bio-therapeutic manufacturing, internationally recognized as a leading expert in cutting-edge biomanufacturing technologies. With over 18 years of experience, he has demonstrated excellence in people management, process development, technology transfer, clinical manufacturing, and regulatory filing for biologics CMC. His career is underscored by a notable track record of scientific research, marked by the publication of 35 peer-reviewed articles. Dr. Rahbar’s contributions highlight his commitment to advancing biomanufacturing technologies, establishing him as a leader in the intricacies of bio-therapeutic manufacturing.
ADVISORY BOARD
Ali Tehrani, PhD
Co-Founder and CEO, DCx
Biotherapeutics; Strategic Advisor, Ness
Therapeutics
Dr. Ali Tehrani is the co-founder and Chief Executive Officer of DCx Biotherapeutics and the co-founder and former President and Chief Executive Officer of Zymeworks Inc., which he led from 2003 to 2022. He previously served as a partner at Amplitude Ventures, a Canadian life sciences investment firm.
At Zymeworks, Dr. Tehrani directed the development of protein engineering platforms, advanced multiple therapeutic programs into clinical trials, established strategic partnerships with global pharmaceutical companies, and led the company through its public listing on the New York Stock Exchange.
He holds BSc and MSc degrees in Biochemistry from the University of Massachusetts and a PhD in Microbiology and Immunology from the University of British Columbia. Dr. Tehrani serves on the boards of Creatus Biosciences, QurCan, BIOTECanada, and the National Research Council of Canada.